Phase 4 Heart Disease Trial, Recruiting NCT06249945 Sponsor: National Taiwan University Hospital Condition: Heart Disease
Back to Heart Disease

Phase 4 Heart Disease Trial, Recruiting

NCT06249945
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 20 years of age or older
  • People who have end-stage kidney disease and have been on regular, ongoing dialysis with a stable fluid removal target (dry weight) for the past 6 months
  • People who have previously been diagnosed with a specific type of heart failure called HFpEF, confirmed by a scoring system called the HFA-PEFF diagnostic algorithm (a score of 5 or higher)

Who may not be able to join:

  • People who are under 20 years of age
  • People who are currently pregnant
  • People with the most severe stage of heart failure symptoms (known as NYHA Class IV)
  • People who have been hospitalised for heart failure in the past month
  • People who currently have an active urinary tract infection at the time of assessment
  • People who currently have a known active genital infection
  • People with severe circulation problems in the legs and feet (a condition rated at a serious level called Rutherford category 4–6)
  • People who have had a heart attack, stroke, or mini-stroke (TIA) within the past month
  • People who only recently started regular dialysis within the last 6 months
  • People whose target fluid removal weight has changed by more than 5% of their body weight in the past month
  • People whose heart pumping strength (left ventricular ejection fraction) was recorded at 40% or below on a scan taken within the past month
  • People who have not agreed to give informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Donna SH Lin, MD, Shin Kong Wu Ho-Su Memorial Hospital

Phone: +886912902379

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
5 March 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Mitral early (E) and late (A) diastolic filling velocity ratio (E/A)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov